No Data
No Data
Dimerix to Recruit Adolescents for Kidney Drug Study; Shares Decline 7%
Dimerix (ASX:DXB) plans to recruit adolescent patients between the ages of 12 and 17, for the ACTION3 clinical trial of its kidney drug DMX-200, the biopharmaceutical company said in a Thursday filing
If You Invested $5,000 in This ASX Healthcare Stock a Year Ago, You'd Have $50,833 Now!
The stock in question is clinical stage drug discovery and development company Dimerix Ltd (ASX: DXB).
Dimerix Initiated at Buy by Petra Capital
Dimerix Initiated at Buy by Petra Capital
Euroz Hartleys Adjusts Dimerix's Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy
12:54 AM EDT, 05/29/2024 (MT Newswires) -- Euroz Hartleys Adjusts Dimerix's Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy Price (AUD): $0.40, Change: $+0.01, Percent Change: +2.56%
Dimerix's Middle East Licensing Deal Signals More Agreements to Come -- Market Talk
1840 ET - Dimerix's licensing deal with UAE-based pharmaceutical group Taiba for its DMX-200 treatment of focal segmental glomerulosclerosis, a rare kidney disease, in the Middle East is a positive su
Dimerix Price Target Raised 7.5% to A$0.86/Share by Euroz Hartleys
Dimerix Price Target Raised 7.5% to A$0.86/Share by Euroz Hartleys
No Data